Prospects for the development of epigenetic drugs for CNS conditions

Nature Reviews Drug Discovery

Volumn 14, Issue 7, 2015, Pages 461-474

  Szyf, Moshe ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DECITABINE; DNA METHYLTRANSFERASE ENHANCER; DNA METHYLTRANSFERASE INHIBITOR; FRM 0334; HISTONE DEACETYLASE INHIBITOR; KAINIC ACID; N PHTHALOYLTRYPTOPHAN; NICOTINAMIDE; PSYCHOSTIMULANT AGENT; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE; ENZYME INHIBITOR; SIGNAL PEPTIDE;

ADDICTION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTISM; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CHROMATIN MODIFICATION; CHRONIC PAIN; CIRCADIAN RHYTHM SLEEP DISORDER; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); DEVELOPMENTAL DISORDER; DNA METHYLATION; DNA MODIFICATION; DRUG DEVELOPMENT; DRUG EFFICACY; EARLY LIFE STRESS; EPIGENETICS; EPILEPSY; EVIDENCE BASED MEDICINE; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC REGULATION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MANIA; MEMORY; MENTAL DISEASE; MENTAL HEALTH; META ANALYSIS (TOPIC); NEUROLOGIC DISEASE; NEUROPATHOLOGY; NIEMANN PICK DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; REWARD; SCHIZOPHRENIA; SLEEP DISORDER; TRANSCRIPTION REGULATION; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; PROCEDURES; TRENDS;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DISCOVERY; ENZYME INHIBITORS; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;

EID: 84934443570     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4580     Document Type: Review

References (207)

1. Razin, A., Riggs, A. D. DNA methylation and gene function. Science 210, 604-610 (1980).
2. Kriaucionis, S., Heintz, N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324, 929-930 (2009).
3. Jenuwein, T., Allis, C. D. Translating the histone code. Science 293, 1074-1080 (2001).
4. Lister, R. et al. Global epigenomic reconfiguration during mammalian brain development. Science 341, 1237905 (2013).
5. Hirabayashi, K., Shiota, K., Yagi, S. DNA methylation profile dynamics of tissue-dependent and differentially methylated regions during mouse brain development. BMC Genomics 14, 82 (2013).
6. Guo, J. U. et al. Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain. Nat. Neurosci. 17, 215-222 (2013).
7. Weaver, I. C. et al. Epigenetic programming by maternal behavior. Nat. Neurosci. 7, 847-854 (2004).
8. Suderman, M. et al. Conserved epigenetic sensitivity to early life experience in the rat and human hippocampus. Proc. Natl Acad. Sci. USA 109 (Suppl. 2), 17266-17272 (2012).
9. McGowan, P. O. et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 12, 342-348 (2009).
10. Levenson, J. M. et al. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279, 40545-40559 (2004).
11. Levenson, J. M. et al. Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J. Biol. Chem. 281, 15763-15773 (2006).
12. Day, J. J. et al. DNA methylation regulates associative reward learning. Nat. Neurosci. 16, 1445-1452 (2013).
13. Graff, J. et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483, 222-226 (2012).
14. Rao, J. S., Keleshian, V. L., Klein, S., Rapoport, S. I. Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients. Transl Psychiatry 2, e132 (2012).
15. Chouliaras, L. et al. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Neurobiol. Aging 34, 2091-2099 (2013).
16. Klengel, T. et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat. Neurosci. 16, 33-41 (2013).
17. Mehta, D. et al. Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder. Proc. Natl Acad. Sci. USA 110, 8302-8307 (2013).
18. LaPlant, Q. et al. Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat. Neurosci. 13, 1137-1143 (2010).
19. Guy, J., Gan, J., Selfridge, J., Cobb, S., Bird, A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143-1147 (2007).
20. West, A. C., Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30-39 (2014).
21. Navada, S. C., Steinmann, J., Lubbert, M., Silverman, L. R. Clinical development of demethylating agents in hematology. J. Clin. Invest. 124, 40-46 (2014).
22. Kass, S. U., Landsberger, N., Wolffe, A. P. DNA methylation directs a time-dependent repression of transcription initiation. Curr. Biol. 7, 157-165 (1997).
23. Shukla, S. et al. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 479, 74-79 (2011).
24. Thomassin, H., Flavin, M., Espinas, M. L., Grange, T. Glucocorticoid-induced DNA demethylation and gene memory during development. EMBO J. 20, 1974-1983 (2001).
25. Lu, Y. et al. Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells. Cell Stem Cell 15, 92-101 (2014).
26. McGhee, J. D., Wood, W. I., Dolan, M., Engel, J. D., Felsenfeld, G. A 200 base pair region at the 5? end of the chicken adult ?-globin gene is accessible to nuclease digestion. Cell 27, 45-55 (1981).
27. Felsenfeld, G. Chromatin. Nature 271, 115-122 (1978).
28. Kent, N. A., Adams, S., Moorhouse, A., Paszkiewicz, K. Chromatin particle spectrum analysis: a method for comparative chromatin structure analysis using paired-end mode next-generation DNA sequencing. Nucleic Acids Res. 39, e26 (2011).
29. Finch, J. T. et al. Structure of nucleosome core particles of chromatin. Nature 269, 29-36 (1977).
30. Sarma, K., Reinberg, D. Histone variants meet their match. Nat. Rev. Mol. Cell Biol. 6, 139-149 (2005).
31. Henikoff, S., McKittrick, E., Ahmad, K. Epigenetics, histone H3 variants, and the inheritance of chromatin states. Cold Spring Harb. Symp. Quant. Biol. 69, 235-243 (2004).
32. Wade, P. A., Pruss, D., Wolffe, A. P. Histone acetylation: chromatin in action. Trends Biochem. Sci. 22, 128-132 (1997).
33. Shiio, Y., Eisenman, R. N. Histone sumoylation is associated with transcriptional repression. Proc. Natl Acad. Sci. USA 100, 13225-13230 (2003).
34. Shilatifard, A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 2432, 243-269 (2006).
35. Jenuwein, T. Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol. 11, 266-273 (2001).
36. Nicklay, J. J. et al. Analysis of histones in Xenopus laevis II. Mass spectrometry reveals an index of cell type-specific modifications on H3 and H4. J. Biol. Chem. 284, 1075-1085 (2009).
37. Eberl, H. C., Spruijt, C. G., Kelstrup, C. D., Vermeulen, M., Mann, M. A map of general and specialized chromatin readers in mouse tissues generated by label-free interaction proteomics. Mol. Cell 49, 368-378 (2013).
38. Miao, F., Natarajan, R. Mapping global histone methylation patterns in the coding regions of human genes. Mol. Cell. Biol. 25, 4650-4661 (2005).
39. Pollack, Y., Stein, R., Razin, A., Cedar, H. Methylation of foreign DNA sequences in eukaryotic cells. Proc. Natl Acad. Sci. USA 77, 6463-6467 (1980).
40. Hotchkiss, R. D. The quantitative separation of purines, pyrimidines, and nucleosides by paper chromatography. J. Biol. Chem. 175, 315-332 (1948).
41. Gruenbaum, Y., Stein, R., Cedar, H., Razin, A. Methylation of CpG sequences in eukaryotic DNA. FEBS Lett. 124, 67-71 (1981).
42. Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315-322 (2009).
43. Drahovsky, D., Morris, N. R. Mechanism of action of rat liver DNA methylase I. Interaction with double-stranded methyl-acceptor DNA. J. Mol. Biol. 57, 475-489 (1971).
44. Cheng, X. DNA modification by methyltransferases. Curr. Opin. Struct. Biol. 5, 4-10 (1995).
45. Comb, M., Goodman, H. M. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res. 18, 3975-3982 (1990).
46. Nan, X. et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386-389; comment 311-312 (1998).
47. Hahn, M. A. et al. Dynamics of 5-hydroxymethylcytosine and chromatin marks in mammalian neurogenesis. Cell Rep. 3, 291-300 (2013).
48. Guo, J. U., Su, Y., Zhong, C., Ming, G. L., Song, H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145, 423-434 (2011).
49. Kohli, R. M., Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502, 472-479 (2013).
50. Picketts, D. J. et al. ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome. Hum. Mol. Genet. 5, 1899-1907 (1996).
51. Berko, E. R. et al. Mosaic epigenetic dysregulation of ectodermal cells in autism spectrum disorder. PLoS Genet. 10, e1004402 (2014).
52. Stefanska, B. et al. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res. 71, 5891-5903 (2011).
53. Matrisciano, F. et al. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology 68, 184-194 (2013).
54. McGowan, P. O. et al. Broad epigenetic signature of maternal care in the brain of adult rats. PLoS ONE 6, e14739 (2011).
55. McGowan, P. O. et al. Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain. PLoS ONE 3, e2085 (2008).
56. Labonte, B. et al. Genome-wide methylation changes in the brains of suicide completers. Am. J. Psychiatry 170, 511-520 (2013).
57. Provencal, N. et al. Association of childhood chronic physicical aggression with a DNA methylation signature in adult human T cells. PLoS ONE 9, e89839 (2014).
58. Guillemin, C. et al. DNA methylation signature of childhood chronic physical aggression in T cells of both men and women. PLoS ONE 9, e86822 (2014).
59. Abel, T., Zukin, R. S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8, 57-64 (2008).
60. Fass, D. M. et al. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology 64, 81-96 (2013).
61. Fischer, A., Sananbenesi, F., Mungenast, A., Tsai, L. H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 31, 605-617 (2010).
62. Fischer, A., Sananbenesi, F., Pang, P. T., Lu, B., Tsai, L. H. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 48, 825-838 (2005).
63. Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., Tsai, L. H. Recovery of learning and memory is associated with chromatin remodelling. Nature 447, 178-182 (2007).
64. Guan, J. S. et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55-60 (2009).
65. Morris, M. J., Mahgoub, M., Na, E. S., Pranav, H., Monteggia, L. M. Loss of histone deacetylase 2 improves working memory and accelerates extinction learning. J. Neurosci. 33, 6401-6411 (2013).
66. Agis-Balboa, R. C., Pavelka, Z., Kerimoglu, C., Fischer, A. Loss of HDAC5 impairs memory function: implications for Alzheimer's disease. J. Alzheimers Dis. 33, 35-44 (2013).
67. Schirrmacher, E. et al. Synthesis and in vitro evaluation of biotinylated RG108: a high affinity compound for studying binding interactions with human DNA methyltransferases. Bioconjug. Chem. 17, 261-266 (2006).
68. Miller, C. A., Sweatt, J. D. Covalent modification of DNA regulates memory formation. Neuron 53, 857-869 (2007).
69. Feng, J. et al. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat. Neurosci. 13, 423-430 (2010).
70. Oliveira, A. M., Hemstedt, T. J., Bading, H. Rescue of aging-associated decline in Dnmt3a2 expression restores cognitive abilities. Nat. Neurosci. 15, 1111-1113 (2012).
71. Taniguchi, M. et al. Histone deacetylase 5 limits cocaine reward through cAMP-induced nuclear import. Neuron 73, 108-120 (2012).
72. McQuown, S. C. et al. HDAC3 is a critical negative regulator of long-term memory formation. J. Neurosci. 31, 764-774 (2011).
73. Rogge, G. A., Singh, H., Dang, R., Wood, M. A. HDAC3 is a negative regulator of cocaine-context-associated memory formation. J. Neurosci. 33, 6623-6632 (2013).
74. Malvaez, M. et al. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc. Natl Acad. Sci. USA 110, 2647-2652 (2013).
75. Brueckner, B. et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 65, 6305-6311 (2005).
76. Miller-Delaney, S. F. et al. Differential DNA methylation patterns define status epilepticus and epileptic tolerance. J. Neurosci. 32, 1577-1588 (2012).
77. Kew, J. N., Kemp, J. A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl.) 179, 4-29 (2005).
78. Machnes, Z. M. et al. DNA methylation mediates persistent epileptiform activity in vitro and in vivo. PLoS ONE 8, e76299 (2013).
79. Friedman, L. K. et al. Kainate-induced status epilepticus alters glutamate and GABAA receptor gene expression in adult rat hippocampus: an in situ hybridization study. J. Neurosci. 14, 2697-2707 (1994).
80. Pellegrini-Giampietro, D. E., Gorter, J. A., Bennett, M. V., Zukin, R. S. The GluR2 (GluR-B) hypothesis: Ca2+-permeable AMPA receptors in neurological disorders. Trends Neurosci. 20, 464-470 (1997).
81. Tanaka, H., Grooms, S. Y., Bennett, M. V., Zukin, R. S. The AMPAR subunit GluR2: still front and center-stage. Brain Res. 886, 190-207 (2000).
82. [No authors listed.] Sodium valproate and clonazepam for epilepsy. Drug Ther. Bull. 13, 97-98 (1975).
83. Godin, Y., Heiner, L., Mark, J., Mandel, P. Effects of Di-n-propylacetate, an anticonvulsive compound, on GABA metabolism. J. Neurochem. 16, 869-873 (1969).
84. Sawaya, M. C., Horton, R. W., Meldrum, B. S. Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA. Epilepsia 16, 649-655 (1975).
85. Gottlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978 (2001).
86. Massart, R. et al. The genome-wide landscape of DNA methylation and hydroxymethylation in response to sleep deprivation impacts on synaptic plasticity genes. Transl Psychiatry 4, e347 (2014).
87. Detich, N., Bovenzi, V., Szyf, M. Valproate induces replication-independent active DNA demethylation. J. Biol. Chem. 278, 27586-27592 (2003).
88. Azzi, A. et al. Circadian behavior is light-reprogrammed by plastic DNA methylation. Nat. Neurosci. 17, 377-382 (2014).
89. Chestnut, B. A. et al. Epigenetic regulation of motor neuron cell death through DNA methylation. J. Neurosci. 31, 16619-16636 (2011).
90. Steffan, J. S. et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 97, 6763-6768 (2000).
91. Zuccato, C. et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J. Neurosci. 27, 6972-6983 (2007).
92. Benn, C. L. et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J. Neurosci. 28, 10720-10733 (2008).
93. Ferrante, R. J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418-9427 (2003).
94. Tajerian, M. et al. DNA methylation of SPARC and chronic low back pain. Mol. Pain 7, 65 (2011).
95. Gruber, H. E. et al. Targeted deletion of the SPARC gene accelerates disc degeneration in the aging mouse. J. Histochem. Cytochem. 53, 1131-1138 (2005).
96. Gruber, H. E., Ingram, J. A., Leslie, K., Hanley, E. N. Jr. Cellular, but not matrix, immunolocalization of SPARC in the human intervertebral disc: decreasing localization with aging and disc degeneration. Spine 29, 2223-2228 (2004).
97. Millecamps, M., Tajerian, M., Sage, E. H., Stone, L. S. Behavioral signs of chronic back pain in the SPARC-null mouse. Spine 36, 95-102 (2011).
98. Tajerian, M. et al. Peripheral nerve injury is associated with chronic, reversible changes in global DNA methylation in the mouse prefrontal cortex. PLoS ONE 8, e55259 (2013).
99. Weaver, I. C., Diorio, J., Seckl, J. R., Szyf, M., Meaney, M. J. Early environmental regulation of hippocampal glucocorticoid receptor gene expression: characterization of intracellular mediators and potential genomic target sites. Ann. NY Acad. Sci. 1024, 182-212 (2004).
100. Weaver, I. C., Meaney, M. J., Szyf, M. Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc. Natl Acad. Sci. USA 103, 3480-3485 (2006).
101. Sio, A. et al. Dysregulated hematopoiesis caused by mammary cancer is associated with epigenetic changes and Hox gene expression in hematopoietic cells. Cancer Res. 73, 5892-5904 (2013).
102. Yoshida, M., Nomura, S., Beppu, T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res. 47, 3688-3691 (1987).
103. Futamura, M. et al. Trichostatin A inhibits both ras-induced neurite outgrowth of PC12 cells and morphological transformation of NIH3T3 cells. Oncogene 10, 1119-1123 (1995).
104. Meade, B. R. et al. Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat. Biotech. 32, 1256-1261 (2014).
105. Serramia, M. J. et al. In vivo delivery of siRNA to the brain by carbosilane dendrimer. J. Control. Release 200, 60-70 (2015).
106. Youn, P., Chen, Y., Furgeson, D. Y. A myristoylated cell-penetrating peptide bearing a transferrin receptor-targeting sequence for neuro-targeted siRNA delivery. Mol. Pharm. 11, 486-495 (2014).
107. d'Ydewalle, C., Bogaert, E., Van Den Bosch, L. HDAC6 at the intersection of neuroprotection and neurodegeneration. Traffic 13, 771-779 (2012).
108. Dobbin, M. M. et al. SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. Nat. Neurosci. 16, 1008-1015 (2013).
109. Bardai, F. H., Price, V., Zaayman, M., Wang, L., D'Mello, S. R. Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. J. Biol. Chem. 287, 35444-35453 (2012).
110. Boyault, C., Sadoul, K., Pabion, M., Khochbin, S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 26, 5468-5476 (2007).
111. Ververis, K., Hiong, A., Karagiannis, T. C., Licciardi, P. V. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7, 47-60 (2013).
112. Nott, A., Watson, P. M., Robinson, J. D., Crepaldi, L., Riccio, A. S-nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature 455, 411-415 (2008).
113. Lee, J. L. Reconsolidation: maintaining memory relevance. Trends Neurosci. 32, 413-420 (2009).
114. Graff, J. et al. Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 156, 261-276 (2014).
115. Nemunaitis, J. J. et al. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J. 9, 58-66 (2003).
116. Haddad, P. M., Das, A., Ashfaq, M., Wieck, A. A review of valproate in psychiatric practice. Expert Opin. Drug Metab. Toxicol. 5, 539-551 (2009).
117. Horowitz, E. et al. Off-label use of sodium valproate for schizophrenia. PLoS ONE 9, e92573 (2014).
118. Costa, E. et al. Epigenetic targets in GABAergic neurons to treat schizophrenia. Adv. Pharmacol. 54, 95-117 (2006).
119. Tremolizzo, L. et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. Natl Acad. Sci. USA 99, 17095-17100 (2002).
120. Tremolizzo, L. et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol. Psychiatry 57, 500-509 (2005).
121. Lipina, T. V. et al. Prophylactic valproic acid treatment prevents schizophrenia-related behaviour in Disc1-L100P mutant mice. PLoS ONE 7, e51562 (2012).
122. Schwarz, C., Volz, A., Li, C., Leucht, S. Valproate for schizophrenia. Cochrane Database Syst. Rev. 3, CD004028 (2008).
123. Wu, J. et al. Class I histone deacetylase inhibitor valproic acid reverses cognitive deficits in a mouse model of septic encephalopathy. Neurochem. Res. 38, 2440-2449 (2013).
124. Amann, B. et al. Anticonvulsants in the treatment of aggression in the demented elderly: an update. Clin. Pract. Epidemiol. Ment. Health 5, 14 (2009).
125. Xiao, H., Su, Y., Cao, X., Sun, S., Liang, Z. A meta-analysis of mood stabilizers for Alzheimer's disease. J. Huazhong Univ. Sci. Technolog. Med. Sci. 30, 652-658 (2010).
126. Hogarth, P., Lovrecic, L., Krainc, D. Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Mov. Disord. 22, 1962-1964 (2007).
127. Lee, A. R. et al. Nicotinamide: a class III HDACi delays in vitro aging of mouse oocytes. J. Reprod. Dev. 59, 238-244 (2013).
128. Liu, D. et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol. Aging 34, 1564-1580 (2013).
129. Chen, M. et al. DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. Mol. Cancer Ther. 11, 370-382 (2012).
130. Yoo, C. B. et al. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev. Res. (Phila.) 1, 233-240 (2008).
131. Cheng, J. C. et al. Preferential response of cancer cells to zebularine. Cancer Cell 6, 151-158 (2004).
132. Cheng, J. C. et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl Cancer Inst. 95, 399-409 (2003).
133. Miller, C. A. et al. Cortical DNA methylation maintains remote memory. Nat. Neurosci. 13, 664-666 (2010).
134. Dong, E., Chen, Y., Gavin, D. P., Grayson, D. R., Guidotti, A. Valproate induces DNA demethylation in nuclear extracts from adult mouse brain. Epigenetics 5, 730-735 (2010).
135. Schwarcz, R., Zaczek, R., Coyle, J. T. Microinjection of kainic acid into the rat hippocampus. Eur. J. Pharmacol. 50, 209-220 (1978).
136. Chik, F., Machnes, Z., Szyf, M. Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine and the DNA methylation inhibitor 5-aza-2?-deoxycytidine. Carcinogenesis 35, 138-144 (2014).
137. Baldessarini, R. J. Neuropharmacology of S-adenosyl-l-methionine. Am. J. Med. 83, 95-103 (1987).
138. Chiang, P. K. et al. S-adenosylmethionine and methylation. FASEB J. 10, 471-480 (1996).
139. Shukeir, N., Pakneshan, P., Chen, G., Szyf, M., Rabbani, S. A. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 66, 9202-9210 (2006).
140. Turner, P., Kantaria, R., Young, A. H. A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective. J. Psychopharmacol. 28, 85-98 (2014).
141. Dording, C. M., Mischoulon, D., Shyu, I., Alpert, J. E., Papakostas, G. I. SAMe and sexual functioning. Eur. Psychiatry 27, 451-454 (2012).
142. Mischoulon, D. et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-l-methionine (SAMe) versus escitalopram in major depressive disorder. J. Clin. Psychiatry 75, 370-376 (2014).
143. Lee, S., Lemere, C. A., Frost, J. L., Shea, T. B. Dietary supplementation with S-adenosyl methionine delayed amyloid and tau pathology in 3xTg-AD mice. J. Alzheimers Dis. 28, 423-431 (2012).
144. Scarpa, S., Cavallaro, R. A., D'Anselmi, F., Fuso, A. Gene silencing through methylation: an epigenetic intervention on Alzheimer disease. J. Alzheimers Dis. 9, 407-414 (2006).
145. Chan, A., Paskavitz, J., Remington, R., Rasmussen, S., Shea, T. B. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am. J. Alzheimers Dis. Other Demen. 23, 571-585 (2008).
146. Remington, R., Chan, A., Paskavitz, J., Shea, T. B. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am. J. Alzheimers Dis. Other Demen. 24, 27-33 (2009).
147. Scarpa, S., Fuso, A., D'Anselmi, F., Cavallaro, R. A. Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease? FEBS Lett. 541, 145-148 (2003).
148. Robinson, L. et al. Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. Brain 135, 2699-2710 (2012).
149. Campbell, R. M., Tummino, P. J. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J. Clin. Invest. 124, 64-69 (2014).
150. Wu, J. C., Santi, D. V. On the mechanism and inhibition of DNA cytosine methyltransferases. Prog. Clin. Biol. Res. 198, 119-129 (1985).
151. Zhang, J. et al. Ezh2 regulates adult hippocampal neurogenesis and memory. J. Neurosci. 34, 5184-5199 (2014).
152. Jones, P. A. Effects of 5-azacytidine and its 2?-deoxyderivative on cell differentiation and DNA methylation. Pharmacol. Ther. 28, 17-27 (1985).
153. Razin, A., Levine, A., Kafri, T., Agostini, S., Cantoni, G. L. DNA hypomethylation and differentiation of Friend erythroleukemia cells. Gene 74, 139-141 (1988).
154. Creusot, F., Acs, G., Christman, J. K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2?-deoxycytidine. J. Biol. Chem. 257, 2041-2048 (1982).
155. Szyf, M., Eliasson, L., Mann, V., Klein, G., Razin, A. Cellular and viral DNA hypomethylation associated with induction of Epstein-Barr virus lytic cycle. Proc. Natl Acad. Sci. USA 82, 8090-8094 (1985).
156. Christman, J. K., Price, P., Pedrinan, L., Acs, G. Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells. Eur. J. Biochem. 81, 53-61 (1977).
157. Wang, D. et al. Peripheral SLC6A4 DNA methylation is associated with in vivo measures of human brain serotonin synthesis and childhood physical aggression. PLoS ONE 7, e39501 (2012).
158. Rakyan, V. K., Down, T. A., Balding, D. J., Beck, S. Epigenome-wide association studies for common human diseases. Nat. Rev. Genet. 12, 529-541 (2011).
159. Paul, D. S., Beck, S. Advances in epigenome-wide association studies for common diseases. Trends Mol. Med. 20, 541-543 (2014).
160. Kuo, M. H., Allis, C. D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20, 615-626 (1998).
161. Lund, A. H., van Lohuizen, M. Epigenetics and cancer. Genes Dev. 18, 2315-2335 (2004).
162. Peters, A. H., Schubeler, D. Methylation of histones: playing memory with DNA. Curr. Opin. Cell Biol. 17, 230-238 (2005).
163. Cheng, X., Collins, R. E., Zhang, X. Structural and sequence motifs of protein (histone) methylation enzymes. Annu. Rev. Biophys. Biomol. Struct. 34, 267-294 (2005).
164. Wang, P. et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol. Cell. Biol. 29, 6074-6085 (2009).
165. Rada-Iglesias, A. et al. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470, 279-283 (2011).
166. Roh, T. Y., Cuddapah, S., Cui, K., Zhao, K. The genomic landscape of histone modifications in human T cells. Proc. Natl Acad. Sci. USA 103, 15782-15787 (2006).
167. Kouzarides, T. SnapShot: histone-modifying enzymes. Cell 128, 802 (2007).
168. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400 (2012).
169. Brownell, J. E. et al. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 84, 843-851 (1996).
170. Yang, X. J., Seto, E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26, 5310-5318 (2007).
171. Holbert, M. A., Marmorstein, R. Structure and activity of enzymes that remove histone modifications. Curr. Opin. Struct. Biol. 15, 673-680 (2005).
172. Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159 (2001).
173. Graff, J., Tsai, L. H. The potential of HDAC inhibitors as cognitive enhancers. Annu. Rev. Pharmacol. Toxicol. 53, 311-330 (2013).
174. Kim, S., Benguria, A., Lai, C. Y., Jazwinski, S. M. Modulation of life-span by histone deacetylase genes in Saccharomyces cerevisiae. Mol. Biol. Cell 10, 3125-3136 (1999).
175. Viswanathan, M., Kim, S. K., Berdichevsky, A., Guarente, L. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev. Cell 9, 605-615 (2005).
176. Rogina, B., Helfand, S. L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl Acad. Sci. USA 101, 15998-16003 (2004).
177. Gupta, S. et al. Histone methylation regulates memory formation. J. Neurosci. 30, 3589-3599 (2010).
178. Okano, M., Bell, D. W., Haber, D. A., Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247-257 (1999).
179. Bhattacharya, S. K., Ramchandani, S., Cervoni, N., Szyf, M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature 397, 579-583 (1999).
180. Razin, A. et al. Replacement of 5-methylcytosine by cytosine: a possible mechanism for transient DNA demethylation during differentiation. Proc. Natl Acad. Sci. USA 83, 2827-2831 (1986).
181. Jost, J. P., Siegmann, M., Sun, L., Leung, R. Mechanisms of DNA demethylation in chicken embryos. Purification and properties of a 5-methylcytosine-DNA glycosylase. J. Biol. Chem. 270, 9734-9739 (1995).
182. Ma, D. K. et al. Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. Science 323, 1074-1077 (2009).
183. Baubec, T., Ivanek, R., Lienert, F., Schubeler, D. Methylation-dependent and-independent genomic targeting principles of the MBD protein family. Cell 153, 480-492 (2013).
184. Hellman, A., Chess, A. Gene body-specific methylation on the active X chromosome. Science 315, 1141-1143 (2007).
185. Gelfman, S., Cohen, N., Yearim, A., Ast, G. DNA-methylation effect on co-transcriptional splicing is dependent on GC-architecture of the exon-intron structure. Genome Res. 23, 789-799 (2013).
186. Han, L., Witmer, P. D., Casey, E., Valle, D., Sukumar, S. DNA methylation regulates microRNA expression. Cancer Biol. Ther. 6, 1284-1288 (2007).
187. Amir, R. E. et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185-188; comment 127-128 (1999).
188. Chahrour, M. et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224-1229 (2008).
189. Gibbons, R. J. et al. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat. Genet. 24, 368-371 (2000).
190. Nan, X. et al. Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc. Natl Acad. Sci. USA 104, 2709-2714 (2007).
191. Jin, B. et al. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Hum. Mol. Genet. 17, 690-709 (2008).
192. Moarefi, A. H., Chedin, F. ICF syndrome mutations cause a broad spectrum of biochemical defects in DNMT3B-mediated de novo DNA methylation. J. Mol. Biol. 409, 758-772 (2011).
193. Petrij, F. et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376, 348-351 (1995).
194. Park, E. et al. Epigenetic mechanisms of Rubinstein-Taybi syndrome. Neuromolecular Med. 16, 16-24 (2014).
195. Verhoeven, W. M., Tuinier, S., Kuijpers, H. J., Egger, J. I., Brunner, H. G. Psychiatric profile in Rubinstein-Taybi syndrome. A review and case report. Psychopathology 43, 63-68 (2010).
196. Lasalle, J. M. Autism genes keep turning up chromatin. OA Autism 1, 14 (2013).
197. Zhu, L. et al. Epigenetic dysregulation of SHANK3 in brain tissues from individuals with autism spectrum disorders. Hum. Mol. Genet. 23, 1563-1578 (2013).
198. Wang, X. et al. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum. Mol. Genet. 20, 3093-3108 (2011).
199. Ladd-Acosta, C. et al. Common DNA methylation alterations in multiple brain regions in autism. Mol. Psychiatry 19, 862-871 (2013).
200. Shulha, H. P. et al. Epigenetic signatures of autism: trimethylated H3K4 landscapes in prefrontal neurons. Arch. Gen. Psychiatry 69, 314-324 (2012).
201. Mill, J. et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am. J. Hum. Genet. 82, 696-711 (2008).
202. Veldic, M., Guidotti, A., Maloku, E., Davis, J. M., Costa, E. In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc. Natl Acad. Sci. USA 102, 2152-2157 (2005).
203. Grayson, D. R. et al. Reelin promoter hypermethylation in schizophrenia. Proc. Natl Acad. Sci. USA 102, 9341-9346 (2005).
204. Auta, J. et al. DNA-methylation gene network dysregulation in peripheral blood lymphocytes of schizophrenia patients. Schizophr. Res. 150, 312-318 (2013).
205. Tochigi, M. et al. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol. Psychiatry 63, 530-533 (2007).
206. Kurita, M. et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 15, 1245-1254 (2012).
207. Rothstein, M. A., Cai, Y., Marchant, G. E. Ethical implications of epigenetics research. Nat. Rev. Genet. 10, 224 (2009).